MedTrace Logo

B7-H3.CD28Z.CART in Solid Tumors

NCT07358260 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-22

No results posted yet for this study

Summary

The goal of this research study is to test if a new cell therapy (B7-H3.CD28Z.CART / B7-H3 CAR T cells) is safe and effective in treating children and young adults with solid cancers whose tumors have returned or stopped responding to standard treatments (relapsed or refractory) and have been identified with a B7-H3 marker.

The names of the treatment interventions used in this study are:

* B7-H3.CD28Z.CART / B7-H3 CAR T cells
* Fludarabine
* Cyclophosphamide

Conditions

Interventions

BIOLOGICAL

B7-H3.CD28Z.CART

Modified autologous T cells administered via Intravenous (IV) infusion

DRUG

Fludarabine

Administered intravenously

DRUG

Cyclophosphamide

Administered intravenously

Sponsors & Collaborators

  • Band of Parents

    collaborator UNKNOWN

  • Robbie Majzner

    lead OTHER

Principal Investigators

  • Natalie Collins, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
9 Months
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-12-31
Completion
2031-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07358260 on ClinicalTrials.gov